BC Innovations | Oct 31, 2019
Distillery Therapeutics

GCCR inhibition could treat Ewing sarcoma

DISEASE CATEGORY: Cancer INDICATION: Bone cancer A team from the Weizmann Institute showed that GCCR inhibitors could be repurposed to treat Ewing sarcoma. The GCCR inhibitor Mifegyne mifepristone decreased proliferation in cultures of human Ewing...
BC Extra | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....
BC Innovations | Apr 2, 2019
Distillery Therapeutics

New glucocorticoid to treat steroid-resistant asthma

DISEASE CATEGORY: Inflammation INDICATION: Asthma In vitro and mouse studies identified a glucocorticoid ligand of GCCR that could help treat steroid-resistant asthma. Optimization of a previously reported synthetic glucocorticoid and in vitro testing in binding...
BC Week In Review | Nov 9, 2018
Clinical News

Clearside discontinues combo therapy for retinal vein occlusion

Clearside Biomedical Inc. (NASDAQ:CLSD) discontinued development of Xipere (formerly CLS-TA) plus Eylea aflibercept to treat macular edema following retinal vein occlusion (RVO) after the combination missed the primary endpoint in the Phase III SAPPHIRE trial....
BC Innovations | Oct 4, 2018
Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Bioinformatics screens; cellular assays; gene profiling A single-cell, sequencing-based method that correlates RNA expression with chromatin accessibility could help identify biomarkers of cellular activity and/or cell type. The method involves: distributing extracted cell nuclei...
BC Week In Review | Sep 28, 2018
Financial News

Perceptive leads Lyra's $29.5M series B

Ears, nose and throat disease company Lyra Therapeutics Inc. (Watertown, Mass.) raised $29.5 million in a series B round led by Perceptive Advisors. Fellow new investors RA Capital, ArrowMark Partners and Soleus Capital also participated,...
BC Extra | Sep 26, 2018
Financial News

Perceptive leads Lyra’s $29.5M series B

Ears, nose and throat disease company Lyra Therapeutics Inc. (Watertown, Mass.) raised $29.5 million in a series B round led by Perceptive Advisors. Fellow new investors RA Capital, ArrowMark Partners and Soleus Capital also participated,...
BC Week In Review | Aug 31, 2018
Clinical News

MC2's non-greasy psoriasis cream superior to Taclonex in Phase III

MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a single-blind Phase...
BC Extra | Aug 21, 2018
Clinical News

MC2's non-greasy psoriasis cream superior to Taclonex

MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a Phase III...
BC Week In Review | Jul 6, 2018
Clinical News

AZ's MEDI0382 reduces glucose and body weight in Phase IIa for Type II diabetes

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said once-daily 200 µg subcutaneous MEDI0382 significantly reduced glucose area under the curve (AUC) from 0-4 hours after a Mixed Meal Tolerance Test (MMTT) (32.8% vs....
Items per page:
1 - 10 of 153